LMNB1, a potential marker for early prostate cancer progression

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Prostate cancer (PC) lacks reliable biomarkers to distinguish aggressive from indolent forms, leading to overtreatment.
• Nuclear lamin B1 (LMNB1) has been implicated in PC progression, but previous findings are inconsistent.

Purpose of the Study:

• To investigate the role of LMNB1 in prostate cancer progression.
• To determine if LMNB1 overexpression alone can induce malignant transformation in benign prostate cells.

Main Methods:

• Generated a LMNB1-overexpressing cell line (LMN-EP156T) from benign prostatic epithelial cells.
• Assessed the tumorigenic potential of LMN-EP156T cells in vitro (soft agar) and in vivo (xenograft mouse model).
• Performed immunohistochemical staining of LMNB1 in patient-derived PC tissues and correlated with Gleason scores and biochemical recurrence (BCR).

Main Results:

• LMNB1-overexpressing cells showed increased proliferation but failed to form colonies in soft agar or establish tumors/metastasis in mice.
• Higher LMNB1 staining intensity in PC specimens correlated significantly with higher Gleason scores.
• Univariate analysis identified pathological stage, resection margin, and extracapsular extension as BCR predictors; LMNB1 showed a non-significant trend.
• Multivariate analysis confirmed pathological stage as the sole significant independent predictor of BCR.

Conclusions:

• LMNB1 may contribute to early-stage prostate cancer progression.
• Additional molecular alterations are likely required for prostate cancer to acquire full malignant potential.
• LMNB1's role in PC progression warrants further investigation, particularly in conjunction with other genetic changes.